Urgent Warning: AI Assistants' Omission of Drug Contraindications Poses Silent Public Health Risk

A critical new analysis reveals that public-facing AI assistants are inadvertently creating a dangerous post-market safety channel through the omission of medication contraindications. This oversight, where AI fails to include safety-critical information readily available in approved product labeling, poses a significant, yet currently under-monitored, risk to patient safety. While much attention has focused on AI hallucinations or outright incorrect outputs, the subtle but equally perilous act of omission has largely been overlooked.

The paper argues that such AI-mediated omissions constitute a genuine pharmacovigilance failure. Patients and caregivers are increasingly turning to AI for medication guidance prior to consulting healthcare professionals, making the accuracy and completeness of AI responses paramount. The absence of crucial warnings, such as drug interactions or specific patient group contraindications, can lead to severe adverse drug events and undermine public trust in AI's role within healthcare.

To address this emergent threat, the research introduces Reasoning Claim Tokens (RCTs) as an innovative solution. RCTs are conceptualized as evidentiary artifacts capable of detecting, documenting, and auditing these safety omissions. Crucially, this method does not necessitate access to the AI model's internal workings or operational control over third-party systems, making it a highly practical and implementable approach for pharmaceutical manufacturers. The ability to audit these omissions retrospectively offers a new layer of accountability and safety monitoring that is desperately needed.

The analysis meticulously situates this AI-mediated omission risk within the established framework of pharmacovigilance doctrine. It clarifies the intricate governance implications arising from the detectability, repeatability, and foreseeability of such AI failures. By outlining these principles, the paper provides a roadmap for industry stakeholders and regulatory bodies to develop robust policies and monitoring strategies. The urgency of this issue cannot be overstated; as AI's presence in healthcare information dissemination expands, ensuring the integrity and completeness of its outputs becomes a foundational pillar of patient protection. Proactive measures, such as those detailed in this research, are vital to mitigate potential harm and uphold the highest standards of drug safety.